Novo Nordisk | NVO - Current Liabilities


Novo Nordisk reported DKK36.54B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
ANI Pharmaceuticals USD 283.65M 44.14M Jun/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Bausch Health Companies USD 4.54B 14M Jun/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Corcept Therapeutics USD 153.8M 4.62M Jun/2026
Drreddys Laboratories INR 167.57B 165.8B Mar/2026
Eli Lilly USD 47B 745M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Merck USD 27.73B 786M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Novo Nordisk DKK 36.54B 188.62B Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
Perrigo USD 1.05B 57.2M Jun/2026
Phibro Animal Health USD 316.47M 34.6M Jun/2026
Prestige Brands USD 153.81M 32.88M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026
Zoetis USD 2.06B 8M Jun/2026